TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration.
Saved in:
| Title: | TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration. |
|---|---|
| Authors: | Regillo C; Retina Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA. cregillo@midatlanticretina.com., Kaiser PK; Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA., Kertes PJ; The John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada., Gillies M; Clinical Ophthalmology and Eye Health, Sydney Eye Hospital, The University of Sydney, Sydney, Australia., Maio-Twofoot T; Novartis Pharma AG, Basel, Switzerland., Lawrence D; Novartis Pharma AG, Basel, Switzerland., Holz FG; Department of Ophthalmology, University of Bonn, Bonn, Germany. |
| Source: | Eye (London, England) [Eye (Lond)] 2026 Feb; Vol. 40 (3), pp. 369-375. Date of Electronic Publication: 2025 Dec 18. |
| Publication Type: | Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study; Comparative Study |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8703986 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5454 (Electronic) Linking ISSN: 0950222X NLM ISO Abbreviation: Eye (Lond) Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1476-5454 |
|---|---|
| DOI: | 10.1038/s41433-025-04161-x |
